pills-384846_960_720-300x200-4567758If Governor Cuomo succeeds in imposing a surcharge on prescription opioids, state government would largely be taxing itself.

This is because the state’s Medicaid health plan for the low-income and disabled covers fully one-third of the state’s population—and therefore buys roughly one-third of the opioids. Plus, New York might not be able to split the cost with the federal government, as it usually does, which would double the bottom-line impact on state finances.

Consider the example of oxycodone, a popular opioid pain reliever. In the first six months of 2017, New York’s Medicaid program paid for 22.8 million oxycodone pills, federal records show. Assuming those pills were 15 milligrams each (one of the smaller dosages), that equates to 513 “morphine milligram equivalents,” or MMEs.

Thus Cuomo’s proposed tax of 2 cents per MME would amount to about $10.3 million—for half a year of a single opioid.

Normally, Washington provides matching aid equal to about 50 percent of New York’s Medicaid costs. But the feds might well refuse to reimburse this tax, as explained in a memorandum of opposition from the drug manufacturers’ lobby, PhRMA:

In calculating the federal share of assistance, Medicaid generally deducts revenues from health-care related taxes imposed by the state or local government unless such taxes are broad and uniform across an entire ‘class’ of items or services and meet certain other requirements. In this case, the tax is applied to a small subset of a class, the first sale of an opioid medication in the State. Absent a special approval from CMS [the Centers for Medicare & Medicaid Services], revenue from the first sale tax could therefore likely be offset by reductions in how much the federal government pays New York for Medicaid assistance.

The Cuomo administration has argued that the tax will be paid by organizations higher up in the chain of distribution, such as wholesalers and distributors, rather than end buyers. His proposed legislation says the opioid tax should be imposed on the first sale to a New York entity, and “shall not be added as a separate charge or line item on any invoice given to the customers or otherwise passed down to the customer.”

But his budget briefing book says, “This surcharge is expected to provide a financial disincentive for the use of these drugs”—which only makes sense if the cost is passed along to buyers.

Realistically, there is no way for the state to prevent the entities who pay the tax from building it into the prices they charge. That means the cost ultimately will fall not just those who overuse or abuse opioids, but also on those who take them legitimately.

Of the $125 million in projected revenue, Medicaid could expect to pay about one-third, or $42 million. The rest would fall on ordinary consumers. Among the targets would be terminally ill patients in hospice care and addicts in rehab using buprenorphine, an opioid-based medication, to help kick the habit.

Another question for lawmakers to consider is where the money would go. The governor proposes to put the revenue in a dedicated “Opioid Prevention, Treatment and Recovery Fund.” Yet his budget does not increase spending on drug treatment by $125 million, meaning the tax would mostly replace existing treatment funds rather than supplementing them.

In effect, the state would be taxing opioid buyers—including, most prominently, itself—to balance the budget.

About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

Even With Federal Cuts, New York’s Health Funding Would Remain High

New York's health-care industry stands to lose billions of dollars in federal funding under the major budget bill being debated in Washington – a rare and jarring turn of events for a sector accustomed to steadily increas Read More

As Albany’s Session Ends, Watch for Rising Health Costs

Every session of the state Legislature brings a fresh crop of proposals that would drive up health-care costs, and 2025 is no exception. Here is a sampling of pending bills that, if Read More

House Budget Would Burst New York’s Essential Plan Bubble

The extraordinary cash bonanza associated with New York's Essential Plan – which has generated billions more than state officials were able to spend – would come to a crashing end under the budget bill advancing in Cong Read More

The House GOP’s Shrinking Budget Plan Could Still Cost New York Billions

The likely impact of federal health-care cutbacks has diminished in recent days as House Republican leaders backed away from some of their bigger-ticket proposals, reducing the estimated savings to $625 billion from previous figures of $715 billion and $8 Read More

Feds Move To Close Medicaid’s ‘MCO Tax’ Loophole, Spelling Trouble for New York

New York's budget has sprung its first major leak just five days after being finalized by Governor Hochul and the Legislature. On Tuesday, federal officials announced a that would Read More

Highlights of Albany’s Bloated and Belated Budget

The state Legislature approved the last of nine budget bills Thursday evening, 38 days after the start of the fiscal year. Here are some highlights of the fiscal impact of final spending plan: Top lines Read More

How Medicaid ‘Expansion’ Changes Could Affect New York

As House Republicans consider cutbacks to federal Medicaid funding, their focus has turned to the so-called expansion population. Although the details of remain undetermined, the s Read More

How Albany Could Save Millions by Closing a Medicaid Loophole

A glitch in state insurance law is allowing doctors to collect Medicaid fees that are sometimes hundreds of times higher than the program normally pays, costing taxpayers millions of dollars a year. Read More